Medicenna Therapeutics Corp.

Medicenna's President and CEO, Dr. Fahar Merchant, was invited to participate and present at the Brain Cancer Research Roundtable organized by the National Brain Tumor Society (“NBTS”)The focus of the event was to explore ways to expedite…

<!-- Name:DistributionId Value:8752102 --> <!-- Name:EnableQuoteCarouselOnPnr Value:False --> <!-- Name:IcbCode Value:4570 -->…

-- Single agent Anti-PD1-IL-2 BiSKIT™ showed superior efficacy compared to a combination of an anti-PD1 antibody with an IL-2 Superkine in murine models of colon, skin, and breast cancer --IL-4/IL-13 Super-antagonist displayed…

TORONTO and HOUSTON, March 10, 2022 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or “the Company”) (NASDAQ: MDNA TSX: MDNA), a clinical stage immuno-oncology company, today announced that Dr. Fahar Merchant, President,…

TORONTO and HOUSTON, Jan. 17, 2022 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or “the Company”) (NASDAQ: MDNA TSX: MDNA), a clinical stage immuno-oncology company, today announced that Mann Muhsin has resigned as Chief…

-- Peak CD8+ T cell (anti-tumor) / Treg (pro-tumor) ratio increased ~2-3 fold over baseline with MDNA11 treatment in the trial’s first two dose escalation cohorts -- MDNA11-induced increases in CD8+ T and NK cells compare favorably to…

-- ABILITY Study is currently ongoing at clinical trial sites in Australia and previously received FDA clearance to expand to sites in the United States -- Preliminary update on safety and PK/PD data expected by year-end 2021 -- Initial…

TORONTO and HOUSTON, Nov. 18, 2021 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or “the Company”) (NASDAQ: MDNA TSX: MDNA), a clinical stage immuno-oncology company, today announced that John H. Sampson, MD, PhD, MHSc,…

TORONTO and HOUSTON, Sept. 23, 2021 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (NASDAQ: MDNA TSX: MDNA), a clinical stage immuno-oncology company, today announced the appointment of John H. Sampson,…

-  Phase 1/2 ABILITY Study is designed to evaluate MDNA11, a potentially best-in-class IL-2 Superkine, in patients with advanced solid tumors -  Study to start enrollment in the third quarter of 2021 in Australia, with expansion to…